AR016427A1 - CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE. - Google Patents

CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.

Info

Publication number
AR016427A1
AR016427A1 ARP980106090A ARP980106090A AR016427A1 AR 016427 A1 AR016427 A1 AR 016427A1 AR P980106090 A ARP980106090 A AR P980106090A AR P980106090 A ARP980106090 A AR P980106090A AR 016427 A1 AR016427 A1 AR 016427A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
cancer
oligopeptide
prosstata
Prior art date
Application number
ARP980106090A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR016427A1 publication Critical patent/AR016427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un conjugado que es util para el tratamiento de cáncer de prostata que comprende un agente citotoxico alcaloide de vinca que está unido a un oligopéptido,donde el oligopéptido comprende una secuencia de aminoácidos que están proteolíticamentedisocia dos en forma selectiva mediante antígeno libre específico deprostata, donde los medios de adhesion se efectuan a través de un ligador químico, dicho conjugado está caracterizado por la union del oligopéptido al oxígenoen posicion 4 delagente citotox ico alcaloide de vinca, o una sal farmacéuticamente aceptable del mismo, una composicion farmacéutica que los comprende, unprocedimiento para preparar dicha composicion, uso de los mismos para la preparacion de un medicamento.
ARP980106090A 1997-12-02 1998-12-01 CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE. AR016427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
AR016427A1 true AR016427A1 (es) 2001-07-04

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106090A AR016427A1 (es) 1997-12-02 1998-12-01 CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.

Country Status (26)

Country Link
US (2) US20060148718A1 (es)
EP (1) EP1036093A1 (es)
JP (1) JP2001525337A (es)
KR (1) KR100580137B1 (es)
CN (1) CN1181092C (es)
AR (1) AR016427A1 (es)
AU (1) AU744652B2 (es)
BG (1) BG65486B1 (es)
BR (1) BR9815116A (es)
CA (1) CA2311615A1 (es)
DZ (1) DZ2665A1 (es)
EA (1) EA002745B1 (es)
EE (1) EE200000333A (es)
HR (1) HRP20000367A2 (es)
HU (1) HUP0100350A3 (es)
ID (1) ID24735A (es)
IL (1) IL136167A0 (es)
IS (1) IS5502A (es)
NO (1) NO20002804L (es)
NZ (1) NZ504615A (es)
PE (1) PE20000009A1 (es)
PL (1) PL197006B1 (es)
SK (1) SK8282000A3 (es)
TR (1) TR200002260T2 (es)
TW (1) TW577897B (es)
WO (1) WO1999028345A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512171A (en) * 1998-12-11 2004-07-30 Medarex Inc Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
HUE047200T2 (hu) 2007-08-17 2020-04-28 Purdue Research Foundation PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2885006B1 (en) * 2012-08-15 2018-08-08 VisEn Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
EP2992531B1 (en) 2013-04-30 2019-06-19 Hewlett-Packard Enterprise Development LP Memory access rate
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2265476A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
TR200002260T2 (tr) 2000-12-21
EA200000603A1 (ru) 2000-12-25
EA002745B1 (ru) 2002-08-29
IL136167A0 (en) 2001-05-20
KR20010032687A (ko) 2001-04-25
PL197006B1 (pl) 2008-02-29
HRP20000367A2 (en) 2000-12-31
NZ504615A (en) 2003-05-30
KR100580137B1 (ko) 2006-05-16
AU1612399A (en) 1999-06-16
HUP0100350A3 (en) 2001-09-28
HUP0100350A2 (hu) 2001-08-28
PL340768A1 (en) 2001-02-26
EE200000333A (et) 2001-08-15
ID24735A (id) 2000-08-03
BG65486B1 (bg) 2008-09-30
BG104563A (en) 2001-04-30
CN1181092C (zh) 2004-12-22
BR9815116A (pt) 2000-10-10
JP2001525337A (ja) 2001-12-11
US20060148718A1 (en) 2006-07-06
DZ2665A1 (fr) 2003-03-22
EP1036093A1 (en) 2000-09-20
TW577897B (en) 2004-03-01
CA2311615A1 (en) 1999-06-10
NO20002804L (no) 2000-07-21
PE20000009A1 (es) 2000-01-27
AU744652B2 (en) 2002-02-28
US20070021350A1 (en) 2007-01-25
WO1999028345A1 (en) 1999-06-10
NO20002804D0 (no) 2000-05-31
CN1284086A (zh) 2001-02-14
IS5502A (is) 2000-05-19
SK8282000A3 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
ATE245662T1 (de) Avidin-biotin immunokonjugate
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
EP0740650A4 (en) CO-MEDICINAL PRODUCTS USED AS A REGULATED MEDICINE DELIVERY PROCESS
EE200000320A (et) Uudsed ühendid
DE69329735D1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
EE200000378A (et) Adamantaani derivaadid
CA2118032A1 (en) Therapeutic conjugates of toxins and drugs
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
DE69530109D1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
HUP0000651A2 (hu) Konjugátumok prosztatarák kezelésére
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
CA2062582A1 (en) Methods and substances for recruiting therapeutic agents to solid tissues
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
ATE411051T1 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat

Legal Events

Date Code Title Description
FG Grant, registration